Nancy Patel, DO
Pulmonary Disease · Clinton, SCNPI 1912119371
Payments from drug & device makers
Across 708 payments — averaging $3700.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2.1M
- GSK$128K
- Hikma Pharmaceuticals USA$97K
- AbbVie$64K
- AstraZeneca$50K
- Boehringer Ingelheim$47K
- plus $125K from 31 others
Across 17 payments — averaging $7207.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$121K
- GSK$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 51 | $2,108,722 |
| GSK | 139 | $127,669 |
| Hikma Pharmaceuticals USA | 3 | $96,919 |
| AbbVie | 50 | $64,281 |
| AstraZeneca | 117 | $50,021 |
| Boehringer Ingelheim | 41 | $46,823 |
| Insmed, Inc. | 47 | $46,727 |
| Sanofi US Services Inc. | 6 | $21,453 |
| Hoffmann-la Roche Limited | 5 | $16,675 |
| Teva Pharmaceuticals USA, Inc. | 11 | $16,284 |
| Chiesi USA, Inc. | 3 | $12,150 |
| Eli Lilly | 2 | $7,000 |
| Sanofi | 45 | $1,114 |
| Grifols USA, LLC | 42 | $801 |
| Verona Pharma, Inc. | 30 | $582 |
| Regeneron Healthcare Solutions, Inc. | 25 | $562 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $542 |
| Viatris Specialty LLC | 10 | $227 |
| Philips North America LLC | 9 | $197 |
| Sanofi-aventis U.S. LLC | 2 | $156 |
| Amgen | 7 | $149 |
| Mylan Specialty L.p. | 8 | $146 |
| Actelion Pharmaceuticals US, Inc. | 7 | $137 |
| Sunovion Pharmaceuticals Inc. | 7 | $87 |
| Baxter Healthcare | 3 | $87 |
| Genentech USA, Inc. | 3 | $55 |
| Astrazeneca AB | 1 | $50 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Tactile Systems Technology Inc | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $17 |
| Inogen, Inc. | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
How this compares
$2,619,840 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Clinton
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- Charles ThompsonAnderson$7.7M
- David ErbSpartanburg$7.5M
- Richard BoganColumbia$4.8M
- Patrick FlumeCharleston$4.6M
- Michael DenenbergRock Hill$3.1M
- Abhijit RavalAnderson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.